Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Astellas Pharma Inc | INDUSTRY |
| Bristol-Myers Squibb | INDUSTRY |
| Novartis | INDUSTRY |
| Pfizer |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The causes of deterioration of transplanted kidney function are poorly understood. The purpose of this study is to determine the disease processes that cause transplanted kidney dysfunction and loss in patients who received a kidney either recently or over a year prior to entering this study. This study will also identify specific characteristics in kidney transplant recipients that predict whether a kidney transplant will be successful.
Over time, chronic kidney graft dysfunction progressively threatens the long-term survival of a kidney graft. The disease processes behind graft dysfunction are unclear. However, chronic kidney graft dysfunction is likely to be caused by certain definable factors. Such factors may include collagens III and IV, transforming growth factor (TGF)-beta, T and B cell surface markers, cell cycle proteins, fibronectin, and laminin. Determining what disease processes and which specific factors are most responsible for kidney graft dysfunction may help in designing future interventional trials for kidney transplant patients. The purpose of this study is to determine whether clinical, laboratory, and histologic studies at the time of initial graft dysfunction will clarify the processes and factors that lead to deterioration and loss of a kidney graft. This is an observational study that will enroll participants who have recently received kidney transplants (prospective cohort) and participants who have had kidney transplants for a longer period of time and are now experiencing kidney graft dysfunction (retrospective cohort).
The duration of this trial may differ between participants, depending on when deterioration of kidney graft function occurs. Participants will be followed until graft loss or death. There are no exclusive study visits associated with this study. Study data are gathered from routine laboratory follow-up tests completed at the participant's local medical center and from information obtained at the time of kidney biopsy. Participants may need to undergo a kidney biopsy as clinically indicated. At the time of biopsy, participants will also undergo urine and blood collection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Retrospective Cohort | 537 transplant recipient records used retrospectively | ||
| Prospective Cohort | 3137 transplant recipients enrolled prospectively |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Kidney transplant failure | throughout study (for prospective cohort) |
Not provided
Not provided
Inclusion Criteria for Prospective Cohort:
Inclusion Criteria for Retrospective Cohort:
Not provided
Not provided
Not provided
Not provided
Kidney transplant recipients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arthur J. Matas, MD | University of Minnesota | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama - Division of Nephrology | Birmingham | Alabama | 35294 | United States | ||
| University of Iowa - Nephrology Division |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15196079 | Background | Hariharan S, Kasiske B, Matas A, Cohen A, Harmon W, Rabb H. Surrogate markers for long-term renal allograft survival. Am J Transplant. 2004 Jul;4(7):1179-83. doi: 10.1111/j.1600-6143.2004.00484.x. | |
| 15888048 | Background | Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, Rush D. Long-term deterioration of kidney allograft function. Am J Transplant. 2005 Jun;5(6):1405-14. doi: 10.1111/j.1600-6143.2005.00853.x. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000092122 | Bronchiolitis Obliterans Syndrome |
| ID | Term |
|---|---|
| D000092124 | Organizing Pneumonia |
| D001989 | Bronchiolitis Obliterans |
| D001988 | Bronchiolitis |
| D001991 | Bronchitis |
Not provided
Not provided
| Sanofi | INDUSTRY |
Not provided
Not provided
Not provided
Blood and urine specimens.
| Iowa City |
| Iowa |
| 52242 |
| United States |
| Hennepin County Medical Center - Division of Nephrology | Minneapolis | Minnesota | 55415 | United States |
| University of Minnesota Dept of Surgery - Transplantation Division | Minneapolis | Minnesota | 55455 | United States |
| Mayo Clinic - Division of Nephrology | Rochester | Minnesota | 55905 | United States |
| University of Alberta - Division of Nephrology & Immunology | Edmonton | Alberta | T6G 2S2 | Canada |
| Health Sciences Center - Section of Nephrology | Winnipeg | Manitoba | R3A 1R9 | Canada |
| 33675321 | Derived | Matas AJ, Helgeson E, Fieberg A, Leduc R, Gaston RS, Kasiske BL, Rush D, Hunsicker L, Cosio F, Grande JP, Cecka JM, Connett J, Mannon RB. Risk Prediction for Delayed Allograft Function: Analysis of the Deterioration of Kidney Allograft Function (DeKAF) Study Data. Transplantation. 2022 Feb 1;106(2):358-368. doi: 10.1097/TP.0000000000003718. |
| 33273317 | Derived | Grande JP, Helgeson ES, Matas AJ. Correlation of Glomerular Size With Donor-Recipient Factors and With Response to Injury. Transplantation. 2021 Nov 1;105(11):2451-2460. doi: 10.1097/TP.0000000000003570. |
| 30801535 | Derived | Oetting WS, Schladt DP, Dorr CR, Wu B, Guan W, Remmel RP, Ikle D, Mannon RB, Matas AJ, Israni AK, Jacobson PA; DeKAF Genomics and GEN03 Investigators. Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. Transplantation. 2019 Aug;103(8):1591-1602. doi: 10.1097/TP.0000000000002659. |
| 30318646 | Derived | Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant. 2018 Dec;32(12):e13424. doi: 10.1111/ctr.13424. Epub 2018 Oct 31. |
| D001982 |
| Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D006086 | Graft vs Host Disease |
| D007154 | Immune System Diseases |